Dr. Brian P. Freeman, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 908
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IA license MD-36821 -
Hematology & Oncology Physician
IA license 36821 -
Internal Medicine Physician
IA license 36821
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
- Mercyone Des Moines Medical Center Des Moines, IA
- Unitypoint Health - Des Moines Iowa Methodist Medi Des Moines, IA
- Pella Regional Health Center Pella, IA
- Monroe County Hospital Albia, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 908
- Services billed
- 197,715
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20,500 | 18 |
| Injection, pembrolizumab, 1 mg | 18,600 | 34 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15,810 | 22 |
| Injection, paclitaxel protein-bound particles, 1 mg | 11,200 | 13 |
| Injection, iron sucrose, 1 mg | 9,600 | 33 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,740 | 12 |
| Injection, paclitaxel, 1 mg | 5,782 | 16 |
| Injection, denosumab, 1 mg | 4,920 | 38 |
| Injection, aprepitant, 1 mg | 4,160 | 23 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,370 | 98 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Des Moines, IA | 146 |
| Acyclovir Other prescribers in Des Moines, IA | 143 |
| Dexamethasone Other prescribers in Des Moines, IA | 101 |
| Gabapentin Other prescribers in Des Moines, IA | 89 |
| Prochlorperazine Maleate Other prescribers in Des Moines, IA | 83 |
| Prednisone Other prescribers in Des Moines, IA | 70 |
| Hydroxyurea Other prescribers in Des Moines, IA | 65 |
| Ondansetron Hcl Other prescribers in Des Moines, IA | 65 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Des Moines, IA | 52 |
| Lenalidomide | 46 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $63,551 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy f…
AstraZeneca Pharmaceuticals LP - A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lu…
AstraZeneca Pharmaceuticals LP - A phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.